2021
DOI: 10.1016/j.athplu.2021.07.012
|View full text |Cite
|
Sign up to set email alerts
|

The West Midland Familial Hypercholesterolaemia (FH) screening programme: Evaluating the utility of the 12 SNP polygenic risk score (PRS) across ethnic groupings

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Diagnostic labs in the UK are grouping individuals into low (deciles 1–3), intermediate (deciles 4–5) and high (deciles 6–10) polygenic hypercholesterolaemia score categories in order to simplify the classification of polygenic hypercholesterolaemia ( George et al, 2021 ). This also ensures that the discrepancies in the percent of individuals with LDL-C >4.9 mmol/L in each decile are smoothed for the BC and SA ethnic groups.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Diagnostic labs in the UK are grouping individuals into low (deciles 1–3), intermediate (deciles 4–5) and high (deciles 6–10) polygenic hypercholesterolaemia score categories in order to simplify the classification of polygenic hypercholesterolaemia ( George et al, 2021 ). This also ensures that the discrepancies in the percent of individuals with LDL-C >4.9 mmol/L in each decile are smoothed for the BC and SA ethnic groups.…”
Section: Discussionmentioning
confidence: 99%
“…Other studies applied the score to define a polygenic cause of high LDL-C in patients with hypercholesterolaemia ( Amor-Salamanca et al, 2017 ; Saadatagah et al, 2021 ). Two of the current NHS Genomic Laboratory Hubs (GLHs) (South West and North East) are including the 12-SNP score within their diagnostic pipelines ( George et al, 2021 ), demonstrating feasibility of implementation. Clinicians receiving these reports are strongly supportive of the roll out to all GLHs and find them helpful for patient management because of the benefit of being able to offer a genetic explanation for mutation negative patients with a biochemical FH phenotype, which may motivate adherence to lifestyle interventions and cholesterol-lowering therapy ( Kullo et al, 2016 ).…”
Section: Introductionmentioning
confidence: 99%